Observational Study of Vectibix with Chemotherapy for Metastatic Colorectal Cancer Patients

Inclusion Criteria • Subject is ≥ 18 years of age at date of enrolment • Histologically or cytologically confirmed carcinoma of colon or rectum • Subject with metastatic carcinoma of colon or rectum • Confirmed wild-type RAS status of tumour • Subjects whose care will be managed primarily by the enrolling physician and/ or all records will be available • Tumour assessment (ie, computed tomography [CT]/magnetic resonance imaging [MRI]) within 12 weeks (84 days) prior to first Vectibix® infusion. • Subjects treated with at least one infusion of Vectibix® in combination with chemotherapy a maximum of 84 days before entering study: first-line in combination with FOLFOX (folinic acid, leucovorin, fluorouracil [5FU], oxaliplatin) or second-line in combination with FOLFIRI (folinic acid, leucovorin, 5FU, irinotecan) in subjects who have received first–line fluoropyrimidine-based chemotherapy (excluding irinotecan) for treatment of wild-type RAS mCRC per approved prescribing information • Subject or subject’s legally acceptable representative has provided informed consent (for countries where required per local regulations) •Subjects treated with Vectibix® in accordance with the current version of the Summary of Product Characteristics (SmPC) Exclusion Criteria • Ongoing or planned concurrent participation in any clinical study involving Investigational Product that has not been approved by the European Medicines Agency for any indication • Ongoing or planned concurrent participation in any clinical study where the dosing of Vectibix® is determined by the protocol (participation in clinical trials on an approved drug and observational trials are permitted but these cannot mandate how mCRC should be treated)